Literature DB >> 3855485

Uptake of methotrexate linked to polyclonal and monoclonal antimelanoma antibodies by a human melanoma cell line.

P Uadia, A H Blair, T Ghose, S Ferrone.   

Abstract

[3H] Methotrexate [( 3H]MTX) was covalently linked to monoclonal antibody (MoAb) 225.28S against human melanoma, to a rabbit anti-human melanoma IgG absorbed either with human red blood cells (AHMGR) or with red blood cells and a variety of normal human tissues (AHMGR + T), or to normal rabbit IgG (NRG). Human melanoma M21 cells were incubated at 0 degrees C or 37 degrees C with 10 microM free MTX or 10 microM MTX linked to one of the above carriers. The order of net uptake of MTX during 6 hours was MTX-MoAb 225.28S greater than MTX-AHMGR greater than MTX-AHMGR + T greater than MTX-NRG greater than or equal to MTX. This order of uptake by the three antibody conjugates corresponded to the amount of conjugate bound at equilibrium at 0 degrees C and to the immunofluorescence titers. Binding sites for MoAb 225.28S were more efficient for internalization of MTX than were those for the two polyclonal antibody preparations. When M21 cells preloaded with MTX by incubation at a drug concentration of 1.0 or 10 microM were incubated in drug-free medium, the amount of cell-associated MTX rapidly declined to 1.8 pmol/mg protein, i.e., the level of intracellular dihydrofolate reductase (DHFR). However, when cells preloaded to a drug content of 112 pmol/mg protein by incubation with 10 microM MTX linked to AHMGR were transferred to conjugate-free medium, 65 pmol MTX/mg remained cell associated after 12 hours. The efflux was inhibited by chloroquine. Both the efflux medium and M21 cells after a 9.5-hour incubation period had MTX-containing catabolic fragments that inhibited DHFR.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3855485

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  9 in total

Review 1.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

Review 2.  Breast cancer: insights in disease and influence of drug methotrexate.

Authors:  Vítor Yang; Maria João Gouveia; Joana Santos; Beate Koksch; Irina Amorim; Fátima Gärtner; Nuno Vale
Journal:  RSC Med Chem       Date:  2020-05-28

Review 3.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Tissue localization of methotrexate-monoclonal-IgM immunoconjugates: anti-SSEA-1 and MOPC 104E in mouse teratocarcinomas and normal tissues.

Authors:  B Ballou; R Jaffe; S Persiani; W C Shen; J J Langone; H Sands; J M Reilandu; J Curley; T R Hakala
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Regression of human melanoma xenografts in nude mice injected with methotrexate linked to monoclonal antibody 225.28 to human high molecular weight-melanoma associated antigen.

Authors:  T Ghose; S Ferrone; A H Blair; Y Kralovec; M Temponi; M Singh; M Mammen
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Antibody directed targeting of methotrexate-containing small unilamellar vesicles.

Authors:  M Singh; G Faulkner; T I Ghose; M Mezei
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Target-selective cytotoxicity of methotrexate conjugated with monoclonal anti-MM46 antibody.

Authors:  N Endo; Y Takeda; K Kishida; Y Kato; M Saito; N Umemoto; T Hara
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  Hydrolysis of methotrexate-immunoglobulin conjugates by liver homogenates and characterization of catabolites.

Authors:  P O Uadia; A H Blair; T Ghose
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  The effect of an anti-membrane antibody-methotrexate conjugate on the human prostatic tumour line PC3.

Authors:  A J Rowland; M E Harper; D W Wilson; K Griffiths
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.